The test detects the MET protein that is over-expressed in some patients with non-squamous non-small cell lung cancer.

NEW YORK — MDxHealth on Wednesday posted a 22 percent year-over-year increase in its first quarter revenues, topping Wall Street's consensus estimate. For the three-month period ended March 31, ...

EsoGuard esophageal precancer testing volume rose 25 percent to 3,034 tests in the first quarter compared to 2,420 tests in Q1 2024.

Upfront will use the proceeds to accelerate the commercialization of its lateral flow test, called LVOne, for triaging stroke patients in the UK, Europe, and US.